BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics
These guidelines provide evidence-based guidance for UK clinicians prescribing biologics for adult patients with axSpA. This includes the criteria for starting treatment, the choice of drug and assessing response to treatment.
Peripheral SpA and juvenile SpA are outside the scope of these guidelines, and readers are referred to the BSR 2012 guidelines for the management of PsA . While a systematic approach was adopted to assess the efficacy of biologic drugs in axSpA, this did not include a health economic evaluation.
Most safety concerns with anti-TNF therapies are common to their use in all inflammatory conditions, and to avoid overlap between BSR guidelines it has been decided that the generic safety aspects will be addressed by a separate BSR guideline on the safety of biologic therapies in inflammatory arthropathies  (currently under revision). These guidelines therefore consider only those safety aspects of specific relevance to axSpA.